BioCryst Pharmaceuticals BCRX Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions.
The official record: BioCryst Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's unrecognized tax benefits increases resulting from current period tax positions.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's unrecognized tax benefits increases resulting from current period tax positions?
- BioCryst Pharmaceuticals (BCRX) reported unrecognized tax benefits increases resulting from current period tax positions of $96.5K in Q4 2025.
- How has BioCryst Pharmaceuticals's unrecognized tax benefits increases resulting from current period tax positions changed year-over-year?
- BioCryst Pharmaceuticals's unrecognized tax benefits increases resulting from current period tax positions increased by 9.3% year-over-year, from $88.25K to $96.5K.
- What is the long-term trend for BioCryst Pharmaceuticals's unrecognized tax benefits increases resulting from current period tax positions?
- Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's unrecognized tax benefits increases resulting from current period tax positions has grown at a -28.8% compound annual growth rate (CAGR), from $1.5M to $386K.
- What does unrecognized tax benefits increases resulting from current period tax positions mean?
- Measures the increase in liabilities for uncertain tax positions taken during the current reporting period. This reflects the company's assessment of tax positions that may be challenged by tax authorities. High levels of such increases may indicate aggressive tax planning or increased regulatory scrutiny.